Drug intelligence / Profile preview

KT-146

Development stage: Preclinical
Lead developer: Kinnov Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

KT-146 is a preclinical-stage therapeutic candidate being developed by Kinnov Therapeutics for the treatment of fentanyl and opiate addiction. Kinnov's development strategy focuses on the synergistic combination of two existing, off-patent drugs to treat various forms of addiction by modulating the brain's reward and withdrawal circuits. While the specific components and molecular targets of KT-146 have not been disclosed, the program is designed to address the specific challenges of fentanyl abuse within the broader context of the opioid crisis.

Beyond the preview

Go deeper on KT-146.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KT-146.

Explore the full profile